Research from Hyogo Prefectural Amagasaki General Medical Center Yields New Data on Follicular Lymphoma (Retrospective Analysis of the Impact of Bendamustine Dose Reduction and Chemotherapy on the Outcomes of Follicular Lymphoma).

Předmět:	FOLLICULAR lymphoma NON-Hodgkin's lymphoma MEDICAL centers CANCER chemotherapy OLDER people
Zdroj:	Medical Letter on the CDC & FDA; 12/24/2023, p668-668, 1p
Abstrakt:	A new report from the Hyogo Prefectural Amagasaki General Medical Center in Japan presents fresh data on follicular lymphoma, the most common indolent non-Hodgkin's lymphoma that primarily affects the elderly population. The study aimed to analyze the impact of bendamustine delays and dose reduction on the outcome of follicular lymphoma. The research found that chemotherapy delays or bendamustine dose reduction did not adversely affect progression-free survival (PFS), but only chemotherapy delays adversely affected overall survival (OS). The study suggests that reducing the bendamustine dose may be a valid option for vulnerable patients. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu